



CompuMed Contracts Extended with Oklahoma and Arizona Corrections Telemedicine Provides Low Cost Alternatives to Costly In-House Prison Services

LOS ANGELES, Jul 08, 2010 -- CompuMed, Inc. (OTCBB: CMPD) (www.compumed.net), a medical informatics and telemedicine services company, has secured extended contracts to provide its signature CardioGram(TM) electrocardiogram (ECG) remote interpretation systems and over-read services for the Oklahoma Department of Corrections (OKDOC) and Arizona Department of Corrections (ADC) at selected facilities throughout both states. The OKDOC rents 21 CardioGram systems, and the ADC owns 45 CardioGram systems.

Maurizio Vecchione, CompuMed's CEO, said, "The CardioGram helps a facility to gain rapid access to specialists in diagnosing and treating cardiovascular disease. Such access increases the standard of care while minimizing costs and potential liability for the facility."

CompuMed's CardioGram is a portable telemedicine device supported by proprietary work-flow software. CompuMed's traditional core business is providing remote ECG interpretation terminals and related services to medical facilities that may not have access to physicians trained and qualified to interpret ECG results or for whom the costs are prohibitive.

Customers for the company's CardioGram system are typically correctional facilities, ambulatory surgery centers, occupational health clinics, research facilities and physician offices. New markets being targeted are rural health and school based clinics. The CardioGram system reduces healthcare costs significantly by providing remote cardiac screening at the point-of-care and reducing unnecessary transports to emergency rooms.

After patient preparation, the ECG is acquired with the push of a button. The ECG data is digitally transmitted via any phone or Internet connection to the company's computer laboratory for instant analysis. ECG data is interpreted by a sophisticated computer algorithm, and interpretations are available in near real-time at the CardioGram device.

The data and interpretation can then be transferred to an electronic medical record (EMR) via CompuMed's proprietary EMR software solution.

However, the most unique and life-saving feature of the CardioGram is the device's over-read capabilities or "The Doctor Inside(TM)," which immediately engages one of CompuMed's on-call cardiologists to over-read the computerized interpretation. Cardiologist over-reads can be made available to attending physicians at the point-of-care, providing expert interpretations in those situations where the data is ambiguous or difficult to interpret. "The Doctor Inside(TM)" is a key element of CompuMed's unique approach to telemedicine and telecardiology.

About CompuMed:

CompuMed, Inc. (OTCBB: CMPD) develops and markets products and services that combine advanced imaging with medical informatics. Its focus is on analysis and remote monitoring for patients with cardiovascular and musculoskeletal diseases. The company has specialized expertise and intellectual property in telemonitoring imaging and analysis designed to improve healthcare provider workflow and patient care while reducing costs. CompuMed is headquartered in Los Angeles and distributes its products worldwide both directly and through OEM partners. Visit CompuMed at www.compumed.net and follow at Twitter: @compumed. To receive a corporate profile on CompuMed or to learn more about the company's progress, please contact Liolios Group at 949-574-3860 or email info@liolios.com.

Forward Looking Statements

Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the

pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.

Press Contact:

Susan Tellem
Tellem Worldwide
+1 310-313-3444
stellem@tellem.com

Investor Relations Contacts:

Ron Both or Cody Slach
Liolios Group, Inc.
+1 949-574-3860
info@liolios.com